FindTrial
Sign In

Treatment of carbapenem resistant acinetobacter baumanni pneumoniae

Polymyxin B combined with sulbactam versus Polymyxin B combined with tigecycline in the treatment of carbapenem resistant acinetobacter baumanni pneumoniae - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/071992
Enrollment
48
Registered
2024-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B998- Other infectious disease

Interventions

Intervention1: POLYMIXIN-B plus SALBACTAM: POLYMYXIN-B- 20.000U/kg-25,000U/kg loading dose given in 100ml NS over 30 minutes
followed by 12,500-15,000U/kg q12h maintenence dose given in 100ml NS over 2hours SULBACTAM- 3g loading dose(given in 100ml NS over 30 minutes)
3g Q8h(given in 100ml NS over 2h Duration: 7-14 days depending on clinical improvement as per physician choice Control Intervention1: POLYMYXIN-B plus TIGECYCLINE: POLYMYXIN-B- 20.000U/kg-25,000U/kg
followed by 12,500-15,000U/kg q12h maintenence dose given in 100ml NS over 2hours SULBACTAM- POLYMYXIN-B- 20.000U/kg-25,000U/kg loading dose given in 100ml NS over 30 minutes
followed by 12,500-15,000U/kg q12h maintenence dose given in 100ml NS over 2hours TIGECYCLINE- 200mg loading(given in 100ml NS over 30minutes)
100mg q12h(given in 100ml NS over 2h) Duration: 7-14 days depending on clinical improvement as per physician choice Control Intervention2: POLYMYXIN-B PLUS TIGECYCLINE: POLYMYXIN-B- 20.000U/kg-25,000
followed by 12,500-15,000U/kg q12h maintenence dose given in 100ml NS over 2hours TIGECYCLINE- 200mg loading(given in 100ml NS over 30minutes)
100mg q12h(given in 100ml NS over 2h

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of HAP or VAP

Exclusion criteria

Exclusion criteria: Isolation of more than one organism in respiratory specimens CRAB resistant to tigecycline and colistin Pregnant patients Patients not willing to participate in the study

Design outcomes

Primary

MeasureTime frame
ICU MORTALITYTimepoint: At baseline, week 7, week 10 and week 14.—

Secondary

MeasureTime frame
Length of hospital stay Length of ICU stay Number of ventilator days Timepoint: DAY 7 DAY 10 DAY 14—

Countries

India

Contacts

Public ContactDr Sruthi Menon

PSG Hospitals

sruthikwt@gmail.com9500899503

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026